A number of studies have shown the benefit of hypertensive treatment even though the most
common forms of the disease are mild-to-moderate in severity. Considering the overall …

To compare the safety and efficacy of isradipine as an antihypertensive drug, five studies
were performed with other antihypertensive drugs. In each, isradipine was given in doses of …

The antihypertensive activity of a sustained‐release preparation of diltiazem (given each 12
hours) was assessed in 96 patients with supine diastolic blood pressure (BP) between 95 …

The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics
were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and …

After 8 weeks of isradipine, a twice‐a‐day dihydropyridine calcium channel blocker, 49% of
elderly patients showed a complete response (sitting diastolic blood presssure≤ 85 mm Hg) …

Isradipine (Sandoz PN 200‐110), a new dihydropyridine calcium channel antagonist, was
evaluated in a randomized, double‐blind, placebo‐controlled trial for antihypertensive …

The efficacy and tolerability of an infusion of isradipine, a calcium antagonist of the
dihydropyridine type, were tested in patients in hypertensive crisis. Ten patients with …

An open‐label drug substitution study showed that controlled‐release isradipine (Dynacirc‐
CR) can be safely substituted for amlodipine on a mg‐for‐mg basis in patients with mild‐to …

The effects of 10 weeks of treatment with isradipine (ISRP), a new dihydropyridine Ca
antagonist, was evaluated in a prospective, randomized, double-blind, parallel group …

Design. Open long‐term study with parallel groups. Setting. Kungsgärdet Geriatric Hospital,
Uppsala, a tertiary referral hospital. Subjects. Twenty‐six untreated hypertensive subjects …